CSF3 and myelodysplastic syndrome: Here, we present a 68-year-old patient with high-risk MDS who received combination therapy consisting of low-dose decitabine, cytarabine, aclarubicin, granulocyte colony-stimulating factor (G-CSF), and human leukocyte antigen (HLA) haploidentical lymphocyte infusion (HLI).